Colostrinin Distribution in Poland

Date : 06/02/2009 @ 7:50AM
Source : UK Regulatory (RNS & others)
Stock : Regen Therapeut (RGT)
Quote : 0.475  0.0 (0.00%) @ 1:30AM
Regen Therapeutics share price Chart

Colostrinin Distribution in Poland


RNS Number : 2090T 
ReGen Therapeutics PLC 
02 June 2009 

For immediate release 
ReGen Signs Exclusive Distribution Agreement for Colostrinin(TM) in Poland 
ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that it has today 
signed an agreement with Tagerr Polska* for the exclusive distribution and 
marketing of its nutritional supplement Colostrinin(TM) in Poland. This comes 
after a period of test - marketing by Tagerr during which Tagerr also satisfied 
all necessary regulatory requirements to import/distribute the product in 
Poland. To date Colostrinin(TM) is marketed in the US, Canada and Australia 
under the brand name CogniSure(TM) ** and in Cyprus under the brand name 
Cognase(TM) *** as a nutritional supplement to 'support healthy brain ageing and 
cognition in humans'. 
Commenting on this agreement Percy Lomax, Chairman and Chief Executive Officer 
of ReGen said : 
'Poland is the country where Colostrinin(TM) was first discovered and we know 
from various communications that there is significant knowledge of the product 
in Poland. Poland has a population of 38 million people and a Gross Domestic 
Product per Capita of $11,072. As such both Tagerr Polska and ourselves are 
optimistic that the volume of sales here should be significant.' 
*Tagerr Polska is an affliate of Tagerr a professional services and trading 
company established in Köln, Germany. In operation since 1995, Tagerr has 
enjoyed considerable successes in marketing and distributing consumer products, 
including food supplements, in central Europe and Germany. ( 
**Colostrinin(TM) for use as a human nutraceutical is licensed in North America 
and Australasia to Metagenics Inc. of San Clemente, California 
*** Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi 
Pharmaceuticals Ltd ( 
For further information: 
Percy Lomax 
 ReGen Therapeutics Plc 
 Tel No 020 7153 4920 
Roland Cornish/Felicity Geidt 
 Beaumont Cornish Limited 
 Tel No 020 7628 
Nick Bealer/David Scott 
 Alexander David 
 Tel No 020 7448 9820 
Notes to Editors: 
Colostrinin(TM) is derived from colostrum a mammal's first milk after birth and 
is produced in a production line in S Dakota, freeze dried in Oregon and 
tabletted at Metagenics Inc plant in California. Metagenics are the distributors 
in North America and Australia. If full production and sales were achieved on 
North American margins revenue to the Company would be $10 million before 
relatively low head office expenses. It would be possible, by spending around 
another $550,000 to bring production facilities up to a level to generate 
revenue of around $50 million. 
Colostrinin(TM) has been available in the professional channel of the healthcare 
market in North America and Australia for over a year. Although achieving 
professional awareness and endorsement was a necessary first step, retail 
distribution, was always and remains our objective. 
This information is provided by RNS 
            The company news service from the London Stock Exchange 

Regen Therapeutics (LSE:RGT)
Historical Stock Chart

1 Year : From Feb 2017 to Feb 2018

Click Here for more Regen Therapeutics Charts.

Regen Therapeutics (LSE:RGT)
Intraday Stock Chart

Today : Sunday 25 February 2018

Click Here for more Regen Therapeutics Charts.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:us D:20180225 09:53:23